Wiler, Solothurn, Switzerland BZ Bank is the famous Corporate Investor, which was founded in 1985. The company was established in Europe in Switzerland. The main office of represented Corporate Investor is situated in the Wiler.
Considering the real fund results, this Corporate Investor is 60 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.
Among the most successful fund investment fields, there are Software, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most popular portfolio startups of the fund, we may highlight additiv, additiv, Pevion Biotech. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the BZ Bank, startups are often financed by Novartis Venture Fund, LODH Immunology Fund, Reference Capital SA. The meaningful sponsors for the fund in investment in the same round are Pictet Private Equity Investors S.A., Novartis Venture Fund, LODH Immunology Fund. In the next rounds fund is usually obtained by Reference Capital SA, Varuma AG, Rosetta Capital.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Acestream | Delaware, Lewes, United States |
| ADV Partners | China, Hong Kong, Hong Kong Island |
| Carrot Capital Healthcare Ventures | New York, New York, United States |
| Coca-Cola Amatil | Australia, New South Wales, North Sydney |
| GoerTek Inc. | China, Shandong, Weifang |
| Hexagon Investments | Colorado, Denver, United States |
| IoT - Internet of Things Corp | Florida, Miami, United States |
| La Finanziaria Trentina | Italy, Trentino-Alto Adige, Trento |
| Mercury Capital Partners | Buffalo, New York, United States |
| No. 1 Venture | - |
| Pine Venture Partners | - |
| QUAD Investment Management | Seoul, Seoul-t'ukpyolsi, South Korea |
| Red Globe | - |
| SAATCHiNVEST | England, London, United Kingdom |
| Spreds | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
| StandUp Ventures | Canada, Ontario, Toronto |
| Union Bank of Nigeria | Lagos, Lagos, Nigeria |
| Virtu Financial | New York, New York, United States |
| Waste Management | Houston, Texas, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
NovImmune | $21M | 17 Dec 2010 | Geneva, Switzerland | ||
Pevion Biotech | $29M | 13 Aug 2007 | Bern, Bern, Switzerland | ||
NovImmune | $46M | 01 Jun 2006 | Geneva, Switzerland |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
NovImmune | $21M | 17 Dec 2010 | Geneva, Switzerland | ||
Pevion Biotech | $29M | 13 Aug 2007 | Bern, Bern, Switzerland | ||
NovImmune | $46M | 01 Jun 2006 | Geneva, Switzerland |
